CTM期刊 | LRRK2抑制可以通过抑制同源重组介导的DNA 双链断裂修复而增强PARP抑制剂的细胞毒性( 二 )

本文插图

所有这些发现均表明高表达LRRK2的OC患者会通过促进HR而引发对治疗的抵抗。此外LRRK2抑制剂和PARPi联合应用可以作为治疗LRRK2高表达OC患者的新策略。

REFERENCES
1. Bookman MA, Optimal primary therapy of ovarian cancer. Ann Oncol. 2016; 27 (Suppl 1): i58-i62.
2. Network Cancer Genome Atlas Research. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474 (7353):609–615.
3. Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell. 2012;47(4): 497-510.
4. San Filippo J, Sung P, KleinH.Mechanism of eukaryotic homologous recombination. Annu Rev Biochem. 2008;77:229–257.
5. Bitler BG,Watson ZL,Wheeler LJ, BehbakhtK. PARP inhibitors: clinical utility and possibilities of overcoming resistance. Gynecol Oncol. 2017 ; 147(3):695–704.
6. Chen L, Hou J, Zeng X, et al. LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair. Clin Transl Med . 2021;11:e341.

本文插图

本文插图